Connect Biopharma reports Q3 EPS (31c), consensus (24c)

Reports Q3 revenue $16k vs $1.2M last year. “Throughout 2025, we have worked diligently to position Connect for success by activating our Phase 2 Seabreeze STAT studies of rademikibart in participants experiencing acute asthma and chronic obstructive pulmonary disease exacerbations and to further solidify our U.S. presence,” said Barry Quart, Pharm.D., CEO and Director of Connect Biopharma (CNTB). “As we look to the remainder of the year, we are focused on patient recruitment and clinical execution in both studies and expect to deliver topline data in the first half of 2026. We continue to work closely with Simcere in advancing rademikibart in China, making strong progress as Simcere submitted its New Drug Application for the treatment of atopic dermatitis to China’s National Medical Products Administration in July 2025 and continues to progress its Phase 3 asthma maintenance study.”